- Home
- EXK vs ELVN Comparison
EXK vs ELVN Comparison
Compare EXK & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- ELVN
- Stock Information
- Founded
- EXK 1981
- ELVN 2016
- Country
- EXK Canada
- ELVN United States
- Employees
- EXK N/A
- ELVN N/A
- Industry
- EXK Precious Metals
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- ELVN Health Care
- Exchange
- EXK Nasdaq
- ELVN Nasdaq
- Market Cap
- EXK 1.2B
- ELVN 1.1B
- IPO Year
- EXK N/A
- ELVN 2020
- Fundamental
- Price
- EXK $4.28
- ELVN $19.68
- Analyst Decision
- EXK Strong Buy
- ELVN Strong Buy
- Analyst Count
- EXK 3
- ELVN 5
- Target Price
- EXK $6.83
- ELVN $38.20
- AVG Volume (30 Days)
- EXK 9.7M
- ELVN 228.0K
- Earning Date
- EXK 03-11-2025
- ELVN 03-13-2025
- Dividend Yield
- EXK N/A
- ELVN N/A
- EPS Growth
- EXK N/A
- ELVN N/A
- EPS
- EXK N/A
- ELVN N/A
- Revenue
- EXK $217,639,000.00
- ELVN N/A
- Revenue This Year
- EXK $59.94
- ELVN N/A
- Revenue Next Year
- EXK $32.12
- ELVN N/A
- P/E Ratio
- EXK N/A
- ELVN N/A
- Revenue Growth
- EXK 5.93
- ELVN N/A
- 52 Week Low
- EXK $2.40
- ELVN $15.96
- 52 Week High
- EXK $5.67
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- EXK 47.89
- ELVN 42.20
- Support Level
- EXK $4.39
- ELVN $20.23
- Resistance Level
- EXK $4.89
- ELVN $22.12
- Average True Range (ATR)
- EXK 0.26
- ELVN 1.17
- MACD
- EXK -0.05
- ELVN -0.02
- Stochastic Oscillator
- EXK 21.56
- ELVN 6.23
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.